Literature DB >> 16361115

GABAB receptor: a site of therapeutic benefit.

Norman G Bowery1.   

Abstract

Although the presence of functional GABAB receptors in mammalian brain has been known for more than 20 years, there is still only one therapeutic agent in use, baclofen, which mediates its effects directly via this receptor. However, activation of this receptor can produce numerous effects that might be amenable to drug development. Evidence from preclinical studies also suggests that antagonism of the GABAB receptor produces beneficial clinical effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16361115     DOI: 10.1016/j.coph.2005.10.002

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  71 in total

Review 1.  Structure and ligand recognition of class C GPCRs.

Authors:  Lei Chun; Wen-hua Zhang; Jian-feng Liu
Journal:  Acta Pharmacol Sin       Date:  2012-01-30       Impact factor: 6.150

Review 2.  Thirty years beyond discovery--clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Kara R Vogel; Phillip L Pearl; William H Theodore; Robert C McCarter; Cornelis Jakobs; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

3.  GABAB receptor-positive modulators: brain region-dependent effects.

Authors:  Julie G Hensler; Tushar Advani; Teresa F Burke; Kejun Cheng; Kenner C Rice; Wouter Koek
Journal:  J Pharmacol Exp Ther       Date:  2011-09-27       Impact factor: 4.030

4.  Chronic baclofen desensitizes GABA(B)-mediated G-protein activation and stimulates phosphorylation of kinases in mesocorticolimbic rat brain.

Authors:  Bradley M T Keegan; Thomas J R Beveridge; Jeffrey J Pezor; Ruoyu Xiao; Tammy Sexton; Steven R Childers; Allyn C Howlett
Journal:  Neuropharmacology       Date:  2015-02-25       Impact factor: 5.250

Review 5.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 6.  Therapeutic strategies for Alzheimer's disease.

Authors:  Donna M Barten; Charles F Albright
Journal:  Mol Neurobiol       Date:  2008-06-26       Impact factor: 5.590

7.  Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep.

Authors:  Zachary D Brodnik; David L Bernstein; Courtney D Prince; Rodrigo A España
Journal:  Behav Brain Res       Date:  2015-06-03       Impact factor: 3.332

8.  Deletion of phospholipase C beta4 in thalamocortical relay nucleus leads to absence seizures.

Authors:  Eunji Cheong; Yihong Zheng; Kyoobin Lee; Jungryun Lee; Seongwook Kim; Maryam Sanati; Sukyung Lee; Yeon-Soo Kim; Hee-Sup Shin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-02       Impact factor: 11.205

9.  Functioning of the dimeric GABA(B) receptor extracellular domain revealed by glycan wedge scanning.

Authors:  Philippe Rondard; Siluo Huang; Carine Monnier; Haijun Tu; Bertrand Blanchard; Nadia Oueslati; Fanny Malhaire; Ying Li; Eric Trinquet; Gilles Labesse; Jean-Philippe Pin; Jianfeng Liu
Journal:  EMBO J       Date:  2008-04-03       Impact factor: 11.598

Review 10.  Identifying the role of pre-and postsynaptic GABA(B) receptors in behavior.

Authors:  Chelsea R Kasten; Stephen L Boehm
Journal:  Neurosci Biobehav Rev       Date:  2015-08-15       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.